Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice-Reference-Cited by-同舟云学术

Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chow Michael Y. T.¹,Chang Rachel Yoon Kyung¹,Li Mengyu¹,Wang Yuncheng¹,Lin Yu¹,Morales Sandra²,McLachlan Andrew J.³,Kutter Elizabeth⁴,Li Jian⁵⁶^ORCID,Chan Hak-Kim¹^ORCID

Affiliation:

1. Advanced Drug Delivery Group, Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia

2. Phage Consulting, Sydney, New South Wales, Australia

3. Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia

4. The Evergreen State College, Olympia, Washington, USA

5. Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia

6. Department of Microbiology, Monash University, Clayton, Victoria, Australia

Abstract

Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different from antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study was to investigate the in vivo PK and PD profiles of antipseudomonal phage PEV31 delivered by pulmonary route in immune-suppressed mice.

Funder

Department of Health, Australian Government | National Health and Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01470-20

Reference58 articles.

1. Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. Centers for Disease Control and Prevention Atlanta GA. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

2. World Health Organization. 2015. Global action plan on antimicrobial resistance. https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/.

3. The global preclinical antibacterial pipeline

4. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

5. Phage therapy for respiratory infections

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections;Clinical Microbiology Reviews;2024-09-12

2. Host immunity involvement in the outcome of phage therapy against hypervirulent Klebsiella pneumoniae infections;Antimicrobial Agents and Chemotherapy;2024-05-14

3. Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa – A literature review;European Journal of Microbiology and Immunology;2024-02-23

4. The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo;2024-01-27

5. Phage Therapy in Lung Transplantation: Current Status and Future Possibilities;Clinical Infectious Diseases;2023-11-01